A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal

Inclusion Criteria: * Speaks, reads, and understands English or Spanish and is willing and able to provide written informed consent on an institutional review board (IRB)-approved form prior to the initiation of any study procedures; * Male, between the ages of 18-60 years; * No significant abnormal findings at the screening physical examination as evaluated by the Investigator; * Normal laboratory values (or abnormal but not clinically significant) at screening as determined by the Investigator; * Subject is willing to remain in the clinic overnight for the Day 1 and Day 8 visits; * Must be able to swallow gelatin capsules Exclusion Criteria: * Known hypersensitivity to Clomid; * Abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant by the Investigator; * Subject with a significant organ abnormality or disease as determined by the Investigator; * Any medical condition that would interfere with the study as determined by the Investigator; * Slow cytochrome P450 2D6 (CYP2D6) metabolizer * Participation in a clinical trial with investigational medication within 30 days prior to study medication administration; * An acute illness within 5 days of study medication administration; * Positive urine drug screen at the screening visit; * A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude, as determined by the Investigator; * History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary embolism); * History of myocardial infarction, unstable angina, symptomatic heart failure, ventricular dysrhythmia, or known history of QTc interval prolongation; * An employee or family member of an employee of the study site or the Sponsor;